الفهرس 
Evaluation of response to different treatment regimens in patients with burkitt’s lymphoma and mature B - ALL A retrospective study
AbstractOnly 14 pages are availabe for public view
 |  | from | 170 |  |  |
| | | from | 170 | | |
Abstract
This is a retrospective study, based on assessment of patients with burkitt’s lymphoma/ leukemia from 2006 to 2012. This study reports two centers experience of adult burkitt’s lymphoma/ leukemia therapy with two different induction regimens. 47 adult patients with newly diagnosed burkitt’s lymphoma/ leukemia were treated at the Medical oncology departments of NCI, Cairo University and of Zagazig university hospitals. These patients received induction chemotherapy with either modified CALGB 9251 or modified Hyper-CVAD. The complete remission (CR) rate was 76.9% in the modified CALGB 9251 group and 70.6% in the modified Hyper-CVAD group in burkitt’s lymphoma patients. The main cause of death was induction related death due to chemotherapy toxicity in the group of patients who received modified CALGB 9251, but within the group who received modified hyperCVAD the main cause of death was disease progression